A nurse is caring for a client who is receiving basiliximab (Simulect) as part of an immunosuppressive regimen following a kidney transplant. Which finding should the nurse recognize as a potential indication of cytokine release syndrome?

A. Gradual weight gain may indicate fluid retention, a common post-transplant concern, but it is not indicative of cytokine release syndrome (CRS), which typically presents acutely during or shortly after infusion of monoclonal antibodies such as basiliximab. B. These are nonspecific symptoms that do not suggest cytokine release syndrome. CRS is characterized by systemic inflammatory responses rather than changes in appetite or sleep patterns. C. Cytokine release syndrome occurs when infused immunomodulatory or monoclonal antibody therapies trigger rapid release of pro-inflammatory cytokines, leading to acute systemic symptoms such as fever, chills, hypotension, tachycardia, and possible respiratory distress. Symptoms often appear within hours of infusion and require immediate monitoring and management. D. These gastrointestinal symptoms are common post-transplant due to medications, immobility, or dietary changes, but they are not indicative of cytokine release syndrome, which manifests primarily as acute systemic inflammatory symptoms.